Association between pre-HCT MRD, as determined by multiparameter flow cytometry, and post-HCT outcome for AML patients in CR1 and CR2. Estimates of OS (A), DFS (B), cumulative incidence of relapse (C), and cumulative incidence of NRM (D) after myeloablative allogeneic HCT for AML in complete morphologic remission, shown individually for MRD^neg (n = 147; black solid line) and MRD^pos (n = 36; gray solid line) CR1 patients, as well as MRD^neg (n = 52; black dashed line) and MRD^pos (n = 18; gray dashed line) CR2 patients.